Flerie’s portfolio company AnaCardio reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction, and announces SEK 205 million financing round

AnaCardio has successfully completed Part A of the phase 1b/2a GOAL-HF1 study of its novel, selective oral ghrelin receptor agonist in patients with heart failure. AC01 was well-tolerated, there was clear target engagement and exploratory pharmacodynamic measurements indicated increased contractility. This will be further evaluated in Part B of the ongoing trial, in the cohort expansion phase, due to start in early 2025.

In conjunction with this important clinical milestone, the company has completed a SEK 205 M Series A extension financing round, co-led by Novo Holdings, Pureos Bioventures and Sound Bioventures, with participation from current investors Flerie, Industrifonden and Fredrik and Ann-Helene Ljungström.

“We are pleased that given these encouraging results, AC01 can now move into the next phase of clinical development: We also welcome the new investors which further strengthens the syndicate. AnaCardio is now in an excellent position and one step closer to bringing a novel contractile agent to heart failure patients”, commented Mark Quick, Partner at Flerie.

Datum 2025-01-09, kl 10:00
Källa MFN
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet